- Conditions
- HIV, Acute HIV Infection
- Interventions
- Dolutegravir 50 mg, Lamivudine 300 mg, Abacavir 600 mg
- Drug
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 2
- States / cities
- Chapel Hill, North Carolina • Durham, North Carolina
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 82
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- HIV Infections
- Interventions
- DTG/3TC FDC, CAR
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 493 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 16
- States / cities
- Los Angeles, California • Newport Beach, California • San Francisco, California + 12 more
- Conditions
- HIV Infections
- Interventions
- Conventional dolutegravir 10 mg tablet, Conventional dolutegravir 50 mg tablet, Dispersible dolutegravir 5 mg tablet, Conventional dolutegravir 25 mg tablet
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- HIV-1/HBV Co-Infection
- Interventions
- B/F/TAF, Placebo to match DTG, Placebo to match F/TDF, DTG, F/TDF, Placebo to match B/F/TAF
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 244 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 4
- States / cities
- Ft. Pierce, Florida • West Palm Beach, Florida • Berkley, Michigan + 1 more
- Conditions
- HIV-1-infection
- Interventions
- B/F/TAF, F/TAF, DTG, DTG Placebo, F/TAF Placebo, B/F/TAF Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 567 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 66
- States / cities
- Phoenix, Arizona • Los Angeles, California • Oakland, California + 47 more
- Conditions
- HIV-1 Infection
- Interventions
- ABC/DTG/3TC, B/F/TAF, ABC/DTG/3TC Placebo, B/F/TAF Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 631 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 78
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 57 more
- Conditions
- HIV
- Interventions
- dolutegravir, Triumeq, Truvada
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia
- Conditions
- HIV-1 Infection
- Interventions
- ABC/DTG/3TC, B/F/TAF, ABC/DTG/3TC Placebo, B/F/TAF Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 567 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 61
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 48 more
- Conditions
- Infection, Human Immunodeficiency Virus, HIV Infections
- Interventions
- Dolutegravir (DTG), Lamivudine (3TC), Tenofovir disoproxil fumarate/Emtricitabine (TDF/FTC FDC)
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 722 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Los Angeles, California • Sacramento, California + 20 more
- Conditions
- HIV Infections
- Interventions
- GSK3640254, ABC/3TC, FTC/TAF, Dolutegravir, Placebo
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 161 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Ft. Pierce, Florida • Orlando, Florida + 5 more
- Conditions
- HIV-1 Infection
- Interventions
- DTG, F/TAF, B/F/TAF, DTG Placebo, F/TAF Placebo, B/F/TAF Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 657 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 74
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 53 more
- Conditions
- HIV Infections
- Interventions
- Dolutegravir 50 mg twice daily, Dolutegravir placebo twice daily
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 25
- States / cities
- Little Rock, Arkansas • Bakersfield, California • Beverly Hills, California + 21 more
- Conditions
- Infection, Human Immunodeficiency Virus, HIV Infections
- Interventions
- Dolutegravir/abacavir/lamivudine FDC, Atazanavir, Ritonavir, Tenofovir/emtricitabine FDC
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 499 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2022
- U.S. locations
- 37
- States / cities
- Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 31 more
- Conditions
- HIV-1 Infection
- Interventions
- BIC, F/TAF, DTG, BIC Placebo, DTG Placebo, B/F/TAF
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 21
- States / cities
- Phoenix, Arizona • Los Angeles, California • Sacramento, California + 15 more
- Conditions
- HIV-1-infection, Antiviral Drug Adverse Reaction, Vascular Diseases, Cardiovascular Abnormalities, Abnormality of Adipose Tissue, Body Weight Changes, Body Fat Disorder, HIV-Associated Lipodystrophy Syndrome
- Interventions
- Dolutegravir 50 MG, Antiretroviral/Anti HIV
- Drug
- Lead sponsor
- Augusta University
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Augusta, Georgia
- Conditions
- HIV Infection
- Interventions
- dolutegravir, lamivudine, Continue current antiretroviral regimen
- Drug
- Lead sponsor
- Babafemi Taiwo
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 7
- States / cities
- San Diego, California • Atlanta, Georgia • Chicago, Illinois + 4 more
- Conditions
- HIV-infection/AIDS
- Interventions
- Cenicriviroc, Dolutegravir, Midazolam
- Drug
- Lead sponsor
- Tobira Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Infection, Human Immunodeficiency Virus, HIV Infections
- Interventions
- GSK1349572, Raltegravir, GSK1349572 Placebo, Raltegravir Placebo
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 724 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2021
- U.S. locations
- 68
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 52 more
- Conditions
- HIV Infections
- Interventions
- GSK3640254, Dolutegravir, Lamivudine capsules, Lamivudine tablets
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 8
- States / cities
- Bakersfield, California • Palm Springs, California • Denver, Colorado + 5 more
- Conditions
- HIV-1 Infection
- Interventions
- Dolutegravir, Lamivudine
- Drug
- Lead sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 122 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 25
- States / cities
- Los Angeles, California • San Diego, California • Torrance, California + 17 more
- Conditions
- HIV, Tuberculosis
- Interventions
- Bictegravir (BIC), Tenofovir alafenamide (TAF), Long-acting injectable formulation of cabotegravir (CAB LA), Dolutegravir (DTG), Atazanavir/ritonavir (ATV/r), Darunavir/ritonavir (DRV/r), Lopinavir/ritonavir (LPV/r), Cobicistat, Ritonavir, First-Line TB Treatment, Second-Line TB Treatment, Doravirine (DOR)
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- Not listed
- Enrollment
- 205 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 13
- States / cities
- Los Angeles, California • San Diego, California • Aurora, Colorado + 7 more
- Conditions
- Infection, Human Immunodeficiency Virus
- Interventions
- DTG, CBZ
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Infection, Human Immunodeficiency Virus, HIV Infections
- Interventions
- Dolutegravir
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 12 Years to 99 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • San Francisco, California • Denver, Colorado + 17 more
- Conditions
- HIV Infection, LTBI
- Interventions
- Dolutegravir (DTG), Isoniazid (INH), Rifapentine (RPT), Antiretroviral Therapy (ART), Pyridoxine (Vitamin B6)
- Drug · Dietary Supplement
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 2
- States / cities
- San Francisco, California • Houston, Texas